Cost-effectiveness of elbasvir/grazoprevir plus sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina

被引：0
作者：
Bissio, E. [1 ]
Nwankwo, C. [2 ]
Corman, S. [3 ]
Monsanto, H. [4 ]
Montes, J. L. [1 ]
机构：
[1] MSD Argentina, Med Affairs, Munro, Argentina
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Pharmerit Int, Bethesda, MD USA
[4] Merck Sharp & Dohme IA LLC, Latin Amer Hlth Outcomes Res, Carolina, PR USA
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30591-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-138
引用
收藏
页码：S189 / S190
页数：2
相关论文
共 50 条
[41]   Effectiveness and utilization of elbasvir/grazoprevir in HCV genotype 1 and 4 infection in the veteran affairs healthcare system in the United States [J].
Puenpatom, A. ;
Kramer, J. R. ;
Smith, D. ;
Chaudhri, E. ;
El-Serag, H. ;
Kanwal, F. .
JOURNAL OF VIRAL HEPATITIS, 2018, 25 :75-76
[42]   Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study [J].
Gonzalez-Peralta, Regino P. ;
Wirth, Stefan ;
Squires, Robert H. ;
Mutschler, Frauke ;
Lang, Thomas ;
Pawlowska, Malgorzata ;
Sluzewski, Wojciech ;
Majda-Stanislawska, Ewa ;
Fischler, Bjorn ;
Balistreri, William F. ;
Jonas, Maureen M. ;
Blondet, Niviann ;
Rosenthal, Philip ;
Alkhouri, Naim ;
Romero, Rene ;
Grandhi, Anjana ;
Castronuovo, Patricia ;
Caro, Luzelena ;
Du, Lihong ;
Rosenbloom, Daniel I. S. ;
Haber, Barbara A. .
HEPATOLOGY COMMUNICATIONS, 2023, 7 (03)
[43]   A real-world study on the effectiveness of elbasvir/grazoprevir in the treatment of genotype 1 chronic hepatitis C [J].
李宽 .
China Medical Abstracts(Internal Medicine), 2021, 38 (02) :109-109
[44]   Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection [J].
Papudesu, Chandana ;
Kottilil, Shyamasundaran ;
Bagchi, Shashwatee .
HEPATOLOGY INTERNATIONAL, 2017, 11 (02) :152-160
[45]   Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection [J].
Sun, Hung-Yu ;
Cheng, Pin-Nan ;
Tseng, Chiung-Ying ;
Tsai, Wei-Jen ;
Chiu, Yen-Cheng ;
Young, Kung-Chia .
GUT, 2018, 67 (07) :1342-1350
[46]   COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN SCOTLAND [J].
Dillon, J. ;
Treharne, C. ;
Howells, R. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S635-S635
[47]   Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection [J].
Puenpatom, Amy ;
Cao, Yumei ;
Yu, Xian ;
Kanwal, Fasiha ;
El-Serag, Hashem B. ;
Kramer, Jennifer R. .
INFECTIOUS DISEASES AND THERAPY, 2020, 9 (02) :355-365
[48]   Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection [J].
Amy Puenpatom ;
Yumei Cao ;
Xian Yu ;
Fasiha Kanwal ;
Hashem B. El-Serag ;
Jennifer R. Kramer .
Infectious Diseases and Therapy, 2020, 9 :355-365
[49]   COST-EFFECTIVENESS ANALYSIS OF SIMEPREVIR AND SOFOSBUVIR COMBINATION THERAPY FOR THE TREATMENT OF GENOTYPE 1 HCV PATIENTS IN THE DOMINICAN REPUBLIC [J].
Pantiri, K. ;
Westerhout, K. Y. ;
Obando, C. A. .
VALUE IN HEALTH, 2015, 18 (07) :A872-A872
[50]   Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea [J].
Chung, Wankyo ;
Kim, Kyung-Ah ;
Jang, Eun Sun ;
Ki, Moran ;
Choi, Hwa Young ;
Jeong, Sook-Hyang .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) :776-783
12345